Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells.

Bapat AA, Munoz RM, Von Hoff DD, Han H.

PLoS One. 2016 Oct 28;11(10):e0165586. doi: 10.1371/journal.pone.0165586. eCollection 2016.

2.

The Effects of Technology Entrepreneurship on Customers and Society: A Case Study of a Spanish Pharmaceutical Distribution Company.

Muñoz RM, Sánchez de Pablo JD, Peña I, Salinero Y.

Front Psychol. 2016 Jun 28;7:978. doi: 10.3389/fpsyg.2016.00978. eCollection 2016.

3.

Isolation and characterization of muscle fatigue substance with anti-tumor activities.

Munoz RM, Han H, Tegeler T, Petritis K, Von Hoff DD, Hoffman SA.

J Cancer. 2013 May 9;4(4):343-9. doi: 10.7150/jca.5418. Print 2013.

4.

Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells.

Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz RM, Von Hoff DD, Han H.

PLoS One. 2012;7(3):e32783. doi: 10.1371/journal.pone.0032783. Epub 2012 Mar 1.

5.

Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Xie L, Kassner M, Munoz RM, Que QQ, Kiefer J, Zhao Y, Mousses S, Yin HH, Von Hoff DD, Han H.

Biochem Pharmacol. 2012 Feb 15;83(4):452-61. doi: 10.1016/j.bcp.2011.11.005. Epub 2011 Nov 15.

6.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H.

Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8.

7.

[Cidofovir gel 1% for treating papillomavirus lesions in a patient with congenital immunodeficiency].

Muñoz RM, Prado E, Cisneros JM, Bautista FJ.

Enferm Infecc Microbiol Clin. 2010 Mar;28(3):209-10. doi: 10.1016/j.eimc.2009.02.018. Epub 2009 Sep 5. Spanish. No abstract available.

PMID:
19733939
8.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuéllar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME, Moreno HD, López JA, Rodríguez EO, de Hoyos CM, Sacristán MP, Martín MD, Ballesteros EM, Rodríguez PA, Menéndez LF, Rivas RS, del Pino Cuadrado P, Lauffer JC, Solano JJ, Martínez JM, Solano FG, Rodríguez PG, Rodríguez JA, Cano TR, Fortacin MD, Lobeiras JM, Sampedro JM, Bravo AP, Pellicer AF, López MD, Liste JF, Fernández MR, Losada AC, Mendez RV, Romero SA, Blanco JJ, Bonaselt IT, Mahia MC, del Valle EF, Yañez PQ, Camarasa MG, Alonso JA, Mendez GF, Feliz FD, Lamela MA, Piñero MV, Alvarado PF, Gómez IL, Martín PF, Gómez JL, López AG, Jiménez AR, Nafs AE, Barquero NC, Ortiz RF, Noguera JL, Carrasco PR, Muñoz JM, Palma MM, Hortelano CM, Bonome LS, Sevilla JS, Juan JM, Ramos JM, Muñoz JL, Guisasola JE, Vazquez LS, Guerras FC, Nebot FJ, Fernández FJ, Nicolau AL, Subirats RC, Kidias MM, Navarro VF, García BF, del Rosal FM, de Vicente Muñoz T, Ballester JA, Lieb PM, Martel AD, Bea ER, Joaquim IG, Enjuanes FB, Piñol MB, Carbonell EF, Muñoz RM, Giribets CA, Sans LA, Blanco AS, Felipe MA, Muñoz PG, Villanueva AP, Arroyo MB, Borri RC, Fallada SM, Merola MC, Rodon EP, Palmes JR, Martínez EP, Catala JM, Coca AS, Ferrandiz FP, Paya EF, Caballero GI, Bonet AF, Figueras JF, Pagador PM, Garibo MM, Camo VP, Carrillo CS, Valero CP, Rebollo FJ, García Campayo J, Sala Ayma JM, Roig MM, de Uña Mateos MA, Bertolin RG, García AM, Mazo FJ, Velasco JL, Pérez LS, Casado CJ, Barba JJ, Diaz MC, Rubio JP, Mandoli AS, Herrero AU, Martínez AR, Serrano PS, Rodríguez EN, Montesinos JS, Macia JF, Mateos Marcos AM, Soto JV, Dumont MV, Pagan JP, Martínez VB, Santiuste de Pablos M, Delgado CE, Quiles MD, López FJ, Navarro PP, Torres AM, Ingles FJ, Arias-Camison JM, Manzano JC, Peña RV, Guitarte GP, Fontecilla HB, Romero JB, Gil RS, Lozano JM, Adanez LD, Zarranz Herrera-Oria I, Jiménez JP, Vaz FC, García OS, Anton CC, Casula RR, Hernandez MC, Escabias FT, Torresano JR, Pérez-Villamil AH, Estevez L, Figuero MA, Muñoz de Morales A, Calvin JL, Criado MD, Rodríguez VM, Ambrosolio EB, Madera PM, Alfaro GP, Vidal MM, Valtuille AG, Ruiz O, Cabornero GL, Echevarria Martínez de Bujo M, Mallen MJ, Puigros JS, Martorell AL, Forteza AC, Arrebola ER, Rodríguez de la Torre M, Saiz CG, Bardolet I Casas C, Linde ER, De Arce Cordon R, Molina EM, Carazo FJ, Romero JJ, Cano DV, Dorado MS, Velazquez SC, Sánchez AJ, Leon SO, Sánchez KP, Benitez MH, Zugarramurai AI, Contreras MA, De la Varga González M, Marín PB, Robina FG, García MS, Pérez FJ, Bros PC, Gómez AC, de Dios Molina Martín J, Perera JL, Averbach MC, Perera JL, Palancares EG, Gallego de Dios MT, Rojo CF, Iglesias SS, Merino MI, Mestre NP, Urdaniz AP, Sánchez JM, Seco RG, Muñoz JF, Agut MM, Lozano ML, Herguedas FM, Pena AT, García JV, Martínez AV, Sanz Granado OS, Fernández MA, Canseco JM, López PA, Martín MA, Barrio JA, Ubago JG, Bennassar MR, Díez JM, Fleta JL, Fortes FP, López CA, Medina O, Alvarez DF, Roca JM, Valladolid GR, Tavera JA, García-Castrillon Sales JA, Llordes IB, Melgarejo CA, Cañas de la Paz F, Callol VV, García MB, García JB, Leal FJ, Corrales EC, Iglesias ES, Gómez MA, Serrano GG, Chillarón EG, Aguado FJ, Castillo JJ, González AG, Vázquez JG, Peralvarez MB, Diaz MR, Mesa MY, Artiles FJ, Chao MA, Mesa MY, del Rosario Santana P, Escudero MA, Berenguer MM, Llacer JM, Berna JA, Ortiz JB, Pardell LT, Hernández-Alvarez de Sotomayor C, Méndez MR, Garate RC, Múgica BD, González MC, Domingo JP, Navarro CS, Vera GS, Cuquerella MA, Monzo JL, Boada PC, Pérez MF, Parrado EC, Sánchez JJ, Fernández JC; e-STAR Spanish Study Group.

Eur Psychiatry. 2009 Jun;24(5):287-96. doi: 10.1016/j.eurpsy.2008.12.002. Epub 2009 Feb 4.

PMID:
19195847
9.

Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD.

Pancreas. 2008 Oct;37(3):e39-44. doi: 10.1097/MPA.0b013e318176b9ae.

10.

Identification of a novel inhibitor of urokinase-type plasminogen activator.

Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H.

Mol Cancer Ther. 2007 Apr;6(4):1348-56.

11.

Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.

Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H.

Mol Cancer Ther. 2006 Oct;5(10):2450-8.

12.

Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation.

Trujillo J, Ramírez V, Pérez J, Torre-Villalvazo I, Torres N, Tovar AR, Muñoz RM, Uribe N, Gamba G, Bobadilla NA.

Am J Physiol Renal Physiol. 2005 Jan;288(1):F108-16. Epub 2004 Aug 24.

13.

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ.

Mol Cancer Ther. 2004 Apr;3(4):451-7.

14.

Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways.

Acosta JJ, Muñoz RM, González L, Subtil-Rodríguez A, Dominguez-Caceres MA, García-Martínez JM, Calcabrini A, Lazaro-Trueba I, Martín-Pérez J.

Mol Endocrinol. 2003 Nov;17(11):2268-82. Epub 2003 Aug 7.

15.

Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.

Vankayalapati H, Bearss DJ, Saldanha JW, Muñoz RM, Rojanala S, Von Hoff DD, Mahadevan D.

Mol Cancer Ther. 2003 Mar;2(3):283-94.

16.

p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.

Petit T, Bearss DJ, Troyer DA, Munoz RM, Windle JJ.

Mol Cancer Ther. 2003 Feb;2(2):165-71.

17.

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ.

Mol Cancer Ther. 2002 Jun;1(8):565-73. Erratum in: Mol Cancer Ther.2003 Feb;2(2):208.

18.
19.

[Epidemiological aspects of ciprofloxacin-resistant Escherichia coli at a general hospital].

Serrano FJ, Muñoz RM, Vidal SS, Morán FG, García CB, Aznar AB.

Rev Esp Quimioter. 2000 Mar;13(1):44-50. Spanish.

PMID:
10855024
20.

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.

Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E.

Metabolism. 2000 Jun;49(6):709-17.

PMID:
10877194
21.

[Epidemiological aspects of ciprofloxacin-resistant Escherichia coli in a general hospital]

Serrano FJ, Muñoz RM, Vidal SS, Morán FG, García CB, Aznar AB.

Rev Esp Quimioter. 2000 Mar;13(1):44-50. Spanish.

PMID:
10878537
22.

Intestinal involvement by nontuberculous mycobacteria after heart transplantation.

Muñoz RM, Alonso-Pulpón L, Yebra M, Segovia J, Gallego JC, Daza RM.

Clin Infect Dis. 2000 Mar;30(3):603-5. Review. No abstract available.

PMID:
10722455
23.

Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia.

Castejón R, Vargas JA, Romero Y, Briz M, Muñoz RM, Durántez A.

Cytometry. 1999 Oct 15;38(5):224-30.

PMID:
10516608
24.

Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.

Bosch-Marcé M, Poo JL, Jiménez W, Bordas N, Leivas A, Morales-Ruiz M, Muñoz RM, Pérez M, Arroyo V, Rivera F, Rodés J.

J Pharmacol Exp Ther. 1999 Apr;289(1):194-201.

PMID:
10087004
25.

Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion.

Murphy LL, Muñoz RM, Adrian BA, Villanúa MA.

Neurobiol Dis. 1998 Dec;5(6 Pt B):432-46. Review.

PMID:
9974176
26.

Three cases of tuberculosis after heart transplantation in Spain.

Muñoz RM, Pulpón LA, Yebra M, Segovia J, San Martín M, Salas C.

Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):801-6. Review.

PMID:
9923525
27.

[Antiretroviral treatment].

Pardo Serrano FJ, Muñoz RM, Sabater Vidal S, Gil Fortuño M.

Med Clin (Barc). 1998 Nov 14;111(16):637-8. Spanish. No abstract available.

PMID:
9881341
28.

Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs.

de Miguel R, Romero J, Muñoz RM, García-Gil L, González S, Villanua MA, Makriyannis A, Ramos JA, Fernández-Ruiz JJ.

Biochem Pharmacol. 1998 Nov 15;56(10):1331-8.

PMID:
9825732
29.

Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats.

Martín-Calderón JL, Muñoz RM, Villanúa MA, del Arco I, Moreno JL, de Fonseca FR, Navarro M.

Eur J Pharmacol. 1998 Feb 26;344(1):77-86.

PMID:
9580419
30.

[Effects of fiber administration in the prevention of gallstones in obese patients on a reducing diet. A clinical trial].

Morán S, Uribe M, Prado ME, de la Mora G, Muñoz RM, Pérez MF, Milke P, Blancas JM, Dehesa M.

Rev Gastroenterol Mex. 1997 Oct-Dec;62(4):266-72. Spanish.

PMID:
9580234
31.

Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule.

Muñoz P, Muñoz RM, Palomo J, Rodríguez-Creixéms M, Muñoz R, Bouza E.

Medicine (Baltimore). 1997 Nov;76(6):415-22. Review.

32.

Perinatal delta(9)-tetrahydrocannabinol exposure alters the responsiveness of hypothalamic dopaminergic neurons to dopamine-acting drugs in adult rats.

García-Gil L, De Miguel R, Muñoz RM, Cebeira M, Villanua MA, Ramos JA, Fernández-Ruiz JJ.

Neurotoxicol Teratol. 1997 Nov-Dec;19(6):477-87.

PMID:
9392783
33.
34.

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.

Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa MA, Carrera MR, Rodríguez de Fonseca F.

Neuroreport. 1997 Jan 20;8(2):491-6.

PMID:
9080435
35.

In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters.

Uribe-Esquivel M, Moran S, Poo JL, Muñoz RM.

Scand J Gastroenterol Suppl. 1997;222:49-52. doi: 10.1080/00365521.1997.11720718.

PMID:
9145447
36.

Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S.

Mol Cell Biol. 1996 Nov;16(11):6009-19.

37.

Changes in mediobasal hypothalamic dopamine and indoleamine metabolism after superior cervical ganglionectomy of rats.

Esquifino AI, Arce A, Muñoz RM, Villanúa MA, Cardinali DP.

J Neural Transm (Vienna). 1996;103(3):287-98.

PMID:
8739840
38.

Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats.

Rodríguez de Fonseca FR, Villanúa MA, Muñoz RM, San-Martin-Clark O, Navarro M.

Neuroendocrinology. 1995 Jun;61(6):714-21.

PMID:
7659195
39.

Long-term behavioral effects of perinatal exposure to delta 9-tetrahydrocannabinol in rats: possible role of pituitary-adrenal axis.

Rubio P, Rodríguez de Fonseca F, Muñoz RM, Ariznavarreta C, Martín-Calderón JL, Navarro M.

Life Sci. 1995;56(23-24):2169-76.

PMID:
7776846
40.

Sodium benzoate and lactulose for the treatment of hepatic encephalopathy.

Campollo O, Cortéz R, Gutiérrez M, Odor A, Muñoz RM.

J Hepatol. 1994 Dec;21(6):1144. No abstract available.

PMID:
7699242
41.

Wild-type human p53 activates the human epidermal growth factor receptor promoter.

Deb SP, Muñoz RM, Brown DR, Subler MA, Deb S.

Oncogene. 1994 May;9(5):1341-9.

PMID:
8152794
42.

Analysis of the DNA-binding domain of the HSV-1 origin-binding protein.

Martin DW, Muñoz RM, Oliver D, Subler MA, Deb S.

Virology. 1994 Jan;198(1):71-80.

PMID:
8259684
43.
44.

p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein.

Martin DW, Subler MA, Muñoz RM, Brown DR, Deb SP, Deb S.

Biochem Biophys Res Commun. 1993 Aug 31;195(1):428-34.

PMID:
8395834
45.

p53 binds to the TATA-binding protein-TATA complex.

Martin DW, Muñoz RM, Subler MA, Deb S.

J Biol Chem. 1993 Jun 25;268(18):13062-7.

46.

Herpesvirus simiae (B virus): replication of the virus and identification of viral polypeptides in infected cells.

Hilliard JK, Eberle R, Lipper SL, Munoz RM, Weiss SA.

Arch Virol. 1987;93(3-4):185-98.

PMID:
3030236
47.

Rapid identification of herpesvirus simiae (B virus) DNA from clinical isolates in nonhuman primate colonies.

Hilliard JK, Munoz RM, Lipper SL, Eberle R.

J Virol Methods. 1986 Apr;13(1):55-62.

PMID:
3013916

Supplemental Content

Loading ...
Support Center